Ryan Wright
Psychiatry · Newport Beach, CANPI 1154559433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 449 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,483 and has fallen 97.7% since, to $57 in 2023. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$825
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$597
- MDD US Operations, LLC$536
- USWM, LLC$397
- plus $3K from 22 others
What the payments were for
- Food & beverage$7,682100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,314 |
| Otsuka America Pharmaceutical, Inc. | 81 | $1,194 |
| Sunovion Pharmaceuticals Inc. | 42 | $825 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $597 |
| MDD US Operations, LLC | 38 | $536 |
| USWM, LLC | 25 | $397 |
| Johnson & Johnson | 16 | $391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $355 |
| Alkermes, Inc. | 16 | $341 |
| Lundbeck LLC | 18 | $295 |
| Bausch Health US, LLC | 17 | $269 |
| Vanda Pharmaceuticals Inc. | 8 | $204 |
| Adlon Therapeutics L.p. | 9 | $157 |
| Indivior Inc. | 8 | $136 |
| Noven Therapeutics, LLC | 6 | $126 |
| Eisai Inc. | 6 | $110 |
| Gilead | 5 | $103 |
| Neurocrine Biosciences, Inc. | 6 | $100 |
| Brainsway USA Inc | 2 | $49 |
| Novo Nordisk | 2 | $36 |
| OWP Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Noven Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$7,705 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 21 | $395 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Newport Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.